NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.connectbiopharm.comConnect Biopharma Holdings Limited announced that it expects to report topline data from its Phase 2 Seabreeze STAT study in the first half of 2026. This study evaluates the safety and efficacy of rademikibart for patients with chronic obstructive pulmonary disease experiencing acute exacerbations. The study follows the FDA's approval of the final protocol on May 14, 2025, and may have significant implications for treatment options and market position if successful.
Data ReportConnect Biopharma Holdings Limited plans to report data from its Phase 2 trials of rademikibart in the first half of 2026. The trials, which are focused on patients with moderate-to-severe asthma or chronic obstructive pulmonary disease (COPD), involve a single 600 mg subcutaneous dose of the drug administered to patients experiencing acute exacerbations. Each of the two parallel trials will enroll around 160 patients, with the aim of evaluating the medication's efficacy in the aftermath of an exacerbation. This data reporting will be critical for assessing the drug's potential impact on treatment options for these respiratory conditions.
Data Reporting